Janssen Asia Pacific

SEOUL, South Korea, May 28, 2011 - - THIS MEDIA ALERT IS INTENDED FOR HONG KONG, NEW ZEALAND, THE PHILIPPINES, SINGAPORE AND THAILAND ONLY - New Data Presented at World Congress of Dermatology STELARA(R) has shown sustained efficacy in Japanese patients with moderate to severe psoriasis over 12 months according to new data presented today at the World Congress of Dermatology (WCD).[1] Psoriasis, a chronic, immune-mediated disease that results from the overproduction of skin cells, affects 125 million people worldwide.

SEOUL, South Korea, May 27, 2011 - - This Media Alert is Intended for Hong Kong, New Zealand, The Philippines, Singapore and Thailand Only - Data Presented at World Congress of Dermatology Results presented at the World Congress of Dermatology (WCD) show the efficacy and safety of STELARA(R) in psoriasis patients of Japanese, Korean and Taiwanese descent were consistent with those reported in North American and European populations.[1] Psoriasis, a chronic, immune-mediated disease that results from the overproduction of skin cells, affects 125 million people worldwide.

SEOUL, South Korea, May 26, 2011 - - This Media Alert is Intended for Hong Kong, New Zealand, the Philippines, Singapore and Thailand Only - New Data Presented at World Congress of Dermatology New data presented at the World Congress of Dermatology (WCD) have shown treatment with STELARA(R) significantly improved the health-related quality of life in Japanese psoriasis patients.[1] Psoriasis, a chronic, immune-mediated disease that results from the overproduction of skin cells, affects 125 million people worldwide.